Triastek Closes USD 20.4M Pre-C Funding Round

Triastek, a Nanjing, China-based company which specializes in 3D printing for pharmaceutical industry, raised USD 20.4M in Pre-C funding.

The round was led by Guoxin Investment, with participation from Goldmine Multi-Family Office and existing investor Mr. Xiaodong Zheng, president of Shanghai Tofflon Science and Technology Co. Prior to this, Triastek was backed by Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Mr. Xiaodong Zheng, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, and Triwise Capital.

The company intends to use the funds to accelerate the innovation of its solutions for drug development and manufacturing.

Founded by Dr. Senping Cheng, Triastek leverages proprietary 3D printing pharmaceutical technology to design and develop medications for patients. Its proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development methods, enables complex drug delivery and programmed release. The company is also actively developing new technology processes, including Semi-Solid Extrusion, Micro-Injection Molding, and Micro-Droplet Jetting. The combination of these technologies with MED offers a wide range of solutions for pharmaceutical delivery and development needs, such as oral peptides, gastric retention, and high potency products.

Currently, Triastek has established strategic partnerships with Eli Lilly, Merck KGaA, Boehringer Ingelheim, Siemens, and Sperogenix.